A generic minimization random allocation and blinding system on web  by Cai, Hongwei et al.
www.elsevier.com/locate/yjbin
Journal of Biomedical Informatics 39 (2006) 706–719A generic minimization random allocation and blinding system on web
Hongwei Cai a, Jielai Xia b,*, Dezhong Xu c,*, Donghuai Gao a, Yongping Yan c
a Network Center, Fourth Military Medical University, No. 17 Changle West Road, Xi’an, Shaanxi 710032, China
b Department of Health Statistics, Faculty of Preventative Medicine, Fourth Military Medical University,
No. 17 Changle West Road, Xi’an, Shaanxi 710032, China
c Department of Epidemiology, Faculty of Preventative Medicine, Fourth Military Medical University,
No. 17 Changle West Road, Xi’an, Shaanxi 710032, China
Received 1 November 2005
Available online 28 February 2006Abstract
Background. Minimization is a dynamic randomization method for clinical trials. Although recommended by many researchers, the
utilization of minimization has been seldom reported in randomized trials mainly because of the controversy surrounding the validity of
conventional analyses and its complexity in implementation. However, both the statistical and clinical validity of minimization were
demonstrated in recent studies. Minimization random allocation system integrated with blinding function that could facilitate the imple-
mentation of this method in general clinical trials has not been reported.
System overview. The system is a web-based random allocation system using Pocock and Simon minimization method. It also supports
multiple treatment arms within a trial, multiple simultaneous trials, and blinding without further programming.
Methods. This system was constructed with generic database schema design method, Pocock and Simon minimization method and
blinding method. It was coded with Microsoft Visual Basic and Active Server Pages (ASP) programming languages. And all dataset were
managed with a Microsoft SQL Server database. Some critical programming codes were also provided.
Simulations and results. Two clinical trials were simulated simultaneously to test the system’s applicability. Not only balanced groups
but also blinded allocation results were achieved in both trials.
Discussions and conclusions. Practical considerations for minimization method, the beneﬁts, general applicability and drawbacks of the
technique implemented in this system are discussed. Promising features of the proposed system are also summarized.
 2006 Elsevier Inc. All rights reserved.
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The randomized controlled trials (RCTs) are commonly
accepted as the gold standard research method for evaluat-
ing health care interventions. Randomization, which gives
each subject a known (usually equal) chance of being
assigned to any of the treatment groups, is the fundamental
of RCTs [1]. Integrated with blinding, randomization helps
to avoid possible bias in the selection and allocation of sub-1532-0464/$ - see front matter  2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2006.02.015
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E-mail addresses: xiajielai@fmmu.edu.cn (J. Xia), xudezh@fmmu.
edu.cn (D. Xu).jects arising from the predictability of treatment assign-
ments [2]. The beneﬁts of randomization can be
summarized as ‘‘elimination of selection bias between
groups, assurance of blinding and justiﬁcation of random-
ization based tests’’ [1]. Although unrestricted randomiza-
tion provides the best unpredictability and prevention of
bias, it may yield highly disparate sample sizes or great
imbalance on baseline characteristics between treatment
groups by chance especially in smaller sample clinical trials
[3,4]. Thus block randomization is used to ensure that com-
parison groups will be of approximately the same size.
Stratiﬁed randomization, where a separate blocked ran-
domization is performed in each stratum of interest, is
one method of avoiding chance imbalances [5].
Fig. 1. Schematic of system architecture.
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zation method, as the allocation of the next subject is
inﬂuenced by the current balance of the treatment groups.
The minimization method was ﬁrst proposed by Taves [6]
in 1974 and independently described and generalized by
Pocock and Simon [7] in 1975. The features of minimiza-
tion methods and their potential problems have been
comprehensively reviewed by Scott et al. [8] and McEnte-
gart [9]. The advantages of minimization include ‘‘the bal-
anced groups achieved with respect to both the numbers
in each treatment arm and the characteristics of each
group’’ and ‘‘the ability to incorporate more prognostic
factors than for stratiﬁed randomization, which is partic-
ularly valuable in smaller sample trials’’ [8]. The draw-
backs of using minimization include ‘‘controversy
surrounding the validity of conventional analyses follow-
ing minimization’’ [10,11], ‘‘selection bias due to the fact
that next assignment can be predicted in some situations,’’
and ‘‘ the additional organizational complexity with the
potential to harm recruitment and increase costs’’ [8].
However, these disadvantages are also true of other
restricted allocation methods, and should not be weighted
unduly [8].
The statistical comparison of minimization methods,
stratiﬁed randomization and simple randomization was
conducted by Hagino et al. [12] through simulations.
Both the statistical and clinical validity of minimization
were demonstrated in their studies. Although minimiza-
tion is a highly eﬀective method for treatment
allocation and recommended by many commentators
[12–14], the utilization of minimization was seldom
reported [8].
Some random allocation software package or system
using minimization methods had been developed, such
as ‘‘Minim’’ [15], a free DOS (Disk Operating System,
a command line user interface operating system) pro-
gram for randomizing patients to treatment groups by
the method of minimization, where data are saved in a
text ﬁle. Multiple-user and multiple-center are not sup-
ported in this software, and the interface is not friendly.
A web-based minimization random allocation system,
which was developed by Kenjo et al. [16], is the most
integrated and user friendly system available. It was
developed by the Practical Extraction and Report Lan-
guage (PERL) for writing common gateway interface
(CGI) script. Multiple trials were not supported simulta-
neously, nor did it address the blinding of allocation
results from participants. We have been engaged in the
research of the minimization method. A minimization
system on web based on conventional database structure
for two treatments has been published [17]. The number
of patients in each stratum and overall were well bal-
anced between treatment groups in simulations, but only
one clinical trial was supported at one time and the
database structure should be modiﬁed if it was to be
used in another clinical trial. Besides, it did not support
blinding.2. System overview
We have developed a random allocation and blinding
system based on the Pocock and Simon minimization
method that can be used in multiple clinical trials simulta-
neously. This system also supports multiple treatment arms
within a trial and blinding without further programming.
2.1. System architecture
The system is running on two separate servers of Win-
dows 2000 Server operating system. One is the World Wide
Web (WWW) Server running Internet Information Services
(IIS). The other is the Database Server running SQL Server
2000 which can not be accessed from Internet. The system
is available, on-line, to WWW users through Secure Socket
Layer (SSL), which provides the point-to-point communi-
cation security. The schematic of this system is shown in
Fig. 1.
2.2. Deﬁnition of the relationships between users, centers,
and studies
Two types of users, i.e., administrators and common
users, have diﬀerent privileges. Administrative tasks
include viewing, editing, and deleting centers, users and
designing studies. Common tasks include registering new
patients and retrieving masked drug numbers.
A study is assumed to be either a single center study or a
multi-center study. A user can only be allowed to login the
system at one center, while one center may accommodate
more than one user. A common user can participate in
one or more studies from the center he resides. Patients
708 H. Cai et al. / Journal of Biomedical Informatics 39 (2006) 706–719are registered into studies from certain center by common
users. The tables demonstrating the relationships between
users, centers and studies are shown in Fig. 2.
2.3. The management of this system
Managed by administrator, a new study can be initial-
ized in the following approaches:
(1) Centers that will involve in the new study are added.
(2) Users in each center who will access this system as
common users are produced.
(3) Name and parameters of the study are set, such as
block length, treatment numbers, the bias assignment
probability and common users who can register
patients in this study through this system. For the
sake of blind setting, block length should be integral
multiple of treatment numbers so that there would be
equal number of diﬀerent drugs in one block. The
important prognostic factors for the study and asso-
ciated levels in each factor are identiﬁed and added
ﬁrst. Then Inclusion/Exclusion criteria of this study
can be added with a serial number at the head of each
item. The Inclusion/Exclusion criteria will be listed in
web browser in ascending order of the serial numbers.
(4) Blinding. The number of patients that will be recruit-
ed in each participant center should be estimated ﬁrst.
Then consecutive masked drug numbers are pro-
duced according to the expected number of patients
in each center. During the process of trials, new
masked drug numbers would be added should the
drug numbers in certain center be run out.
The management of this system is illustrated in Fig. 3.Fig. 2. Database structure representing relationships between users,
centers and studies.2.4. Patient recruitment and drug allocation process
All patients are recruited by common users. They use
this system in the following steps after logging on
(1) Choose study and input simple demographic infor-
mation about the new patient.
(2) Select items according to the Inclusion/Exclusion
criteria and the system will automatically decide
whether this patient is eligible or not to current
study.
(3) If the patient is eligible, the levels for each prognostic
factors associated with current patient are elected and
submitted. Otherwise, the patient would be kept out
of the randomization process.
(4) After the conﬁrmation of submissions, a masked drug
number is given back to this patient.3. Methods
3.1. Database design
The database structure in this system makes it easy to
accommodate new data items, such as trials, factors, and
levels, without the additional programming that would be
required in a traditional database design.
3.1.1. Relationships of clinical studies and patients
There may be several prognostic factors in one study
and several levels in each factor. Each patient matches with
certain level in any factor. Fig. 4 demonstrates how a
female patient, aged 45 and enrolled from Southern hospi-
tal, is related with a study with 3 factors and 8 levels.
Little modiﬁcation of the database is desirable when
new clinical trial is added. A database structure improved
from Entity-Attribute-Value (EAV) schema was used to
show the relationship of clinical trials and subjects
[18,19]. As illustrated in Fig. 5, each study might contain
several prognostic factors, which were related with the
study by Foreign Key of study_id in factors table. Each
factor might contain several levels, which were related
with the factor by Foreign Key of level_id in levels table.
A row in eav_pa_int table represented a relationship
between certain subject and level. With the matching of
patient_id and level_id, every patient could be located with
the exact levels. The patients having been allocated to cer-
tain treatment at certain level could be identiﬁed by col-
umn of ‘‘treatment’’ and ‘‘level_id’’ combination in
patient_en table and eav_pa_int table. The number of
patients at each level could be ﬁgured out by summing
them up.
3.1.2. Study and Inclusion/Exclusion criteria
Minimization techniques utilize an adaptive schema,
in which the next subject assignment is based on the
current balance of the treatment groups. The appropri-
ate drug number and associated treatment for the next
Fig. 3. Management of minimization random allocation system.
Fig. 4. Relationships between a study and a patient.
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the patient has been conﬁrmed [20]. The database
design showing the relationship between study and
Inclusion/Exclusion criteria was referenced the EAV
structure from TrialDB (TrialDB is an open-source
Clinical Study Data Management System) [19]. This
database structure, illustrated in Fig. 6, also supports
multi-trial.Arbitrary numbers of study criteria for certain study
could be recorded in study_criteria table, where Inclusion
and Exclusion criteria could be distinguished by criteri-
on_des. Criteria for each study could be distinguished by
study_id in study_criteria table. The responses (‘‘0’’ stands
for ‘‘no’’ and ‘‘1’’ stands for ‘‘yes’’) of Inclusion/Exclusion
criteria for all recruited patients were recorded in
patient_study_criteria table.
Fig. 5. Database structure representing relationships between enrolled
patients and studies.
ig. 6. Database structure representing the relationships between studie
nd Include/Exclude criteria.
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a3.2. The statistical method implemented in the computer
program
The system was coded with Microsoft Visual Basic and
Active Server Pages (ASP) programming languages, and
the data were stored in a Microsoft SQL Server database.
Programming was based on Pocock and Simon method,
where treatment assignment depends on three aspects
[7,8]: the amount of variation among assignments for
any given factor level a measure of the total imbalance
in treatment numbers assignment probabilities to the
arms of the trial.
Program ﬂow chart of the computation and allocation
process is shown in Fig. 7.
3.2.1. The computation and comparison of the amount of
variation
Suppose patients are to be assigned to a clinical trial
with N treatment groups and M prognostic factors for
which treatment balance is required, the number of levels
of these factors being n1,n2, . . . ,nM. For an arbitrary point,
let xijk be the number of patients with level j of factor i who
have been assigned treatment k, i=1, 2,. . .,M; j = 1, 2, . . . ,ni
and k = 1, 2, . . . ,N. Suppose the newly registered and eligi-
ble patient is in level r1, r2, . . . ,rM for factors 1,2, . . . ,M.
Deﬁne Gk as the amount of variation the patient brings
suppose it to be assigned to certain treatment. If treatmentk is assigned to the next patient, deﬁne dik as the resultant
of ‘‘lack of balance’’ among treatment assignments for
patients with level ri of factor i. One-way to measure the
total imbalance is to sum up the marginal imbalances.
There may however be situations where some prognostic
factors are considered to be more important than others.
In such cases it is possible to use a weighted sum instead.
The best weights for a given trial can be explored using
simulations [9]. Then the amount of variation
Gk ¼
XM
i¼1
widik ðwi is the weighting of factor iÞ. ð1Þ
Deﬁne Sik, the Standard Deviation of the number of pa-
tients in each factor level, measures the ‘‘amount of varia-
tion’’ at level j in factor i.
d ik ¼ Sik ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N
XN
k¼1
ðxik XiÞ2
vuut ði ¼ 1; 2; . . . ;M .
k ¼ 1; 2; . . . ;N .Þ. ð2Þ
With the product of weighting and Sik for each factor, Eq.
(1) that measures the amount of variation becomes
Gk ¼
XM
i¼1
wiSik ¼
XM
i¼1
wi
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N
XN
k¼1
ðxik XiÞ2
vuut
ði ¼ 1; 2; . . . ;M . k ¼ 1; 2; . . . ;N .Þ. ð3Þ
The programming code to fulﬁll this function is given in
Appendix A.
3.2.2. The choice of assignments probability and allocation
It was recommended that ‘‘Deterministic dynamic allo-
cation procedures should be avoided and an appropriate
eﬀort should be made to be incorporated for each treat-
ment allocation’’ [20]. Therefore, an appropriate assign-
ment probability should be considered to the treatment
arms of the trial.
In our system, the treatment assignment probability is
unvaryingly equal to p if there is only one smallest Gk. Sup-
pose the bias treatment assignment probability is 0.8. As
shown in Fig. 7, if there is only one smallest Gk and the ran-
dom number generated by computer is less than 0.8, the
target treatment is the one matched with the smallest Gk.
If the random number is equal to or more than 0.8, the
treatment number matched with the smallest Gk would be
out. Then assignments would proceed in other residual
treatments in the same way. In other words, there is always
a probability of 80% with which the treatment with the
smallest Gk in the residual treatment number pool is chosen
in each inning. If there is more than one treatment with the
smallest and equal Gk, the new patient would be assigned
into these treatments with equal probability. If the assign-
ment probability is set as 0.5 for a two-treatment clinical
trial, patients will be allocated to treatments by unrestrict-
ed randomization method.
Fig. 7. Program ﬂow chart of the computation and allocation process. Gk: the amount of variation, refer to Eq. (3) Random number: generated by
computer and ranges from 0 to 1. p: the bias assignment probability.
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in Visual Basic Script and embedded in ASP, is given in
Appendix B.
3.3. Blinding methods
The blinding information for all studies is stored in two
tables. One is used for the matching of drug names and
treatment numbers, where a kind of drug is assigned with
a certain treatment number. The other is used for the
matching of drug numbers and treatment numbers, where
each drug number is associated with a treatment number
randomly. The random matching method between drug
numbers and treatment numbers, together with the drug
allocation rule, are explained below.
3.3.1. Drug number producing for each treatment
A Stored Procedure in SQL Server 2000 database was
written for the blinding of drug numbers and treatment
numbers.
It takes four steps to fulﬁll this task in a block of drugs:
study_id and center_id are read from web pages. The
biggest drug number, block number, and block size are read
from database. Drug numbers (for each trial, the value
of drug number starts from 1 and with the increment of
1 automatically for the next drug), block number andcomputer-generated random numbers are inserted into the
blind table. Drug allocation numbers are updated in
blind table according to the rank of random numbers from
small to big ones. Treatment numbers are allocated for
each drug number according to the rank of random num-
bers from small to big ones. The number of diﬀerent drugs
in one block length is set equal.
For a clinical study with 3 treatment groups, if 6 is set as
the block length, there would be 2 (6/3) drug numbers allo-
cated for each treatment in one block. The blinding infor-
mation for 7th to 9th block is demonstrated in Table 1. In
the 7th block (from the 1st to 6th row in Table 1), the drug
numbers (the column of ‘‘Drug number’’) are in ascending
sort from 37 to 42. The rank of drug allocation numbers
(the column of ‘‘All_num’’) are created according to the
order of computer generated random numbers (the column
of ‘‘Ran’’). The smallest two drug allocation numbers are
assigned to treatment 1, the middle two numbers are
assigned to treatment 2, and the biggest two are assigned
to treatment 3. In the end, there are two drugs for each
treatment in the 7th block, and the matching between drug
numbers and drug allocation numbers are randomized.
Drug allocation numbers and associated treatment num-
bers are assigned to other drugs in the same way.
The programming code of the PROCEDURE for set-
ting blind is given in Appendix C.
Table 1
Blind information for the 3rd center in a clinical trial
blind_id center_id study_id patient_id Drug number Block number Allocation number Treatment number Random number
1107 3 1 0 37 7 39 2 0.725715
1108 3 1 0 38 7 40 2 0.810006
1109 3 1 0 39 7 38 1 0.311874
1110 3 1 0 40 7 42 3 0.943732
1111 3 1 0 41 7 41 3 0.872126
1112 3 1 0 42 7 37 1 0.233886
1113 3 1 0 43 8 46 2 0.467334
1114 3 1 0 44 8 47 3 0.699734
1115 3 1 0 45 8 48 3 0.821765
1116 3 1 0 46 8 43 1 4.61E02
1117 3 1 0 47 8 45 2 0.18797
1118 3 1 0 48 8 44 1 8.94E02
1119 3 1 0 49 9 54 3 0.800063
1120 3 1 0 50 9 53 3 0.777643
1121 3 1 0 51 9 50 1 0.332821
1122 3 1 0 52 9 49 1 0.119092
1123 3 1 0 53 9 52 2 0.723484
1124 3 1 0 54 9 51 2 0.472167
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Drugs tagged with drug numbers (each drug number is
associated with a masked treatment) should be transferred
to each participant center according to the blind table. They
are allocated by the order of drug allocation numbers from
small to big.
For example, the blinding information for a study is
demonstrated in Table 1. Suppose drugs allocated to the
3rd center, where center_id is 3, are numbered from 37 to
54. The next patient registered from this center is to be allo-
cated to treatment 1 by calculation of minimization
method. In the blind table, 37 is the smallest drug alloca-
tion number associated with treatment 1 in this center in
unallocated drugs where patient_id is ‘‘0’’ as being set as
default. The drug number associated with that allocation
number is 42. Therefore, drug number 42 is going to be
allocated to this patient. Then the patient_id column in
the corresponding row is updated with the new patient’s
patient_id to indicate that this drug has been allocated.
The residual drug numbers are allocated to the following
patients in the same way.
4. Simulations and results
4.1. Preparations before patients’ recruitment
Two clinical trials were simulated in our system
simultaneously.
There were two treatment groups and three prognostic
factorsknownas ‘‘center, severityof disease andcardiopathy’’
in the ﬁrst trial. ‘‘Severity of disease’’ was considered more
important and the weighting for this factor was set twowhile
the other two factors’ weightings were set 1. There were 5
levels (center 1 to center 5) in factor ‘‘center,’’ 3 levels (Light,
Mild, and Severe) in factor ‘‘severity of disease’’ and 2 levels
(Cardiopathy, No cardiopathy) in factor ‘‘cardiopathy.’’
The bias treatment assignment probability p was set 0.8.Simulation data of 120 patients’ were created by computer
randomly. The total number of patients from center 1 to
center 5 was 30, 18, 24, 22, and 26, respectively. As stated
in Section 2.3, ﬁve centers were added as the participant
centers in this study, adequate masked drug numbers were
produced and allocated to each center in advance. Then ﬁve
common users representing ﬁve centers were created, who
would register patients from ﬁve diﬀerent computers
through web.
There were three treatment groups and three prognostic
factors known as ‘‘sex, age, and center’’ in the second trial.
The weightings were all the same for three prognostic fac-
tors. There were two levels (Male, Female) in factor ‘‘sex,’’
three levels (<40, 40–60, and >60) in factor ‘‘age’’ and three
levels (Xi Jing Hospital, Southern Hospital, and Hua Xi
Hospital) in factor ‘‘center.’’ The bias treatment assign-
ment probability p was set 0.85. Simulation data of 54
patients’ were created by computer. Three users represent-
ing three centers enrolled patients form three diﬀerent com-
puters through web.
4.2. Patients’ recruitment and drug allocation
As stated in Section 2.4, common user logged on this
system after its username and password being veriﬁed.
Then trials’ list appeared in which he had privilege to enroll
patient. After a trial was chosen, new patient’s demograph-
ic data would be input ﬁrst. If the new patient should not
meet the Inclusion/Exclusion criteria, a decline hint would
appear. Otherwise, the randomization process began. After
the patient’s levels in all prognostic factors having been
chosen and submitted, the treatment number that should
be allocated to this patient was calculated by Pocock and
Simon minimization method. Then according to the blind-
ing rule, a masked drug number associated with the calcu-
lated treatment number would be given back to this
patient.
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process, when the computer generated random number
was less than p (0.8), the treatment associated with the small-
estGkwas allocated to the patient, the programoutput infor-
mation of computing process is shown in Fig. 8. For an
arbitrary point in the second trial, the program output infor-
mation of computing process is shown in Fig. 9. The pro-
gram output information is invisible to common users
except the last line.
A common user’s interface of drug allocation results
through Internet Explore is shown in Fig. 10. He would
have no idea of the real treatment applied to each recruitedFig. 8. The program output of the computing proc
Fig. 9. The program output of the computing procespatient, for drug numbers and treatment numbers were
randomly matched.
4.3. Allocation results of simulations
Both trials achieved the balanced groups with respect
to both the numbers in each treatment arm and the char-
acteristics of each group without mutual interference. The
assignment result of the ﬁrst simulated trial with 120
patients is shown in Fig. 11. The assignment result of
the second simulated trial with 54 patients is shown in
Fig. 12.ess and drug allocation result for the ﬁrst trial.
s and drug allocation result for the second trial.
Fig. 10. Masked drug number is given back to the common user.
Fig. 11. Allocation results of the ﬁrst simulated trial with 120 patients.
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As a good car must be driven by a good driver to exert
all its potential, the good manipulation of this system
depends on the investigator’s understanding of the minimi-
zation method. Practical considerations for minimization
include:
(1) Choice of random element. The assignment probabili-
ty is incorporated to reduce the predictability of next
subject while keep good balance between treatmentgroups. However, the predictability of next subject
is decreased with the decrease of the assignment prob-
ability while the imbalance probability among treat-
ment arms increased at the same time. The proper
assignment probability for a clinical trial could be
varied depending on the trial size, number of treat-
ments and number of stratifying factors [9]. Hagino
et al. [12] simulated a team of 4-factor, 12-level and
2-treatment trials with varying assignment probabili-
ties and sample sizes. The allocation probability of
minimization was changed from 1.00 (deterministic
Fig. 12. Allocation results of the second simulated trial with 54 patients.
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patients trails. Each combination was simulated
1000 times, respectively. The p value of thev2 test of
the contingency table formed by simultaneous distri-
bution of multiple prognostic factors and group had
been calculated to evaluate balance in the simulta-
neous distribution. The bigger the p value of v2 test,
the better the balance achieved. If the 1 percentile
of p value of v2 test about 0.50 was chosen as a crite-
rion to achieve a strongly acceptable degree of bal-
ance, the allocation probability of minimization was
required to be set to 0.95 for 50, 0.80 for 100, 0.75
for 150, and 0.70 for 200 patients [12]. Proper alloca-
tion probability should be explored by simulations
after the trial size, number of treatments, number of
factors and levels are decided.
(2) Choice of weightings. Reed and Wickham concluded
that there was no need to useweightings [21].However,
McEntegart argued that they could be useful to satisfy
preferences about the relative merits of achieving bal-
ance at study [9]. It was advised that the bestweightings
for a trial could be explored using simulations [9].
Generic database structure in this system brings the
beneﬁt of keeping the database structure stable while
accommodating arbitrary number of clinical trials with
any number of treatments. The problem of representing
phenotypic data is very similar to the problem of repre-
senting clinical patient data in this system [22,23]. The
same modeling approach can be used in similar situa-
tions in other ﬁelds, such as genetics or genomics data
management. One phenotype does not typically rely on
a single gene, but rather the clustering of several genes
and associate with the disparity in expression levels. Avast number of relative independent parameters (geno-
types) can potentially associated with one or more
patients (phenotypes). With the database design method
in this system, the database structure could keep stable
when new parameters (genotypes) or patients (pheno-
types) being added. However, the database structure
has its drawbacks. All dataset in eav_pa_int table needs
to be scanned and accumulated time after time at the
calculation of each new patient’s assignment. Thus,
response time of this system is mainly spent on the
searches in eav_pa_int table. When the rows in this table
increasing tremendously with new trials and patients
added, the system response time may be a little post-
poned. Therefore, cleaning up of the trials’ data is rec-
ommended after they have been accomplished. Another
so called drawback about the database structure is that
the patients’ allocation data for a certain study must ﬁrst
be extracted into regular table before analyzed.
6. Conclusions
Promising features of the proposed system include: (1)
New clinical trial can be added into this system without
increasing the number of tables in database. (2) It supports
arbitrary number of treatments in each trial. (3) Random-
ization allocation results can be masked without further
programming. (4) Randomization phase begins only after
the determination of subject eligibility for current trial.
(5) Multi-center and multi-user are supported. (6) Partici-
pants can access the Internet-based automated system
through web browser 24 h a day and 7 days a week.
This system described in this paper can be customized
easily and facilitate the utilization of minimization method
in the practice of clinical trials.
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Dim n 0The number of factors in current study
Dim p 0The number of treatment arms in current study
Dim w() 0Redim w(n) The weighting of each factors in current study
Dim s() 0Redim s(n,p) The number of patient in each factor levels and treatments already being recruited
Dim x() 0Redim x(n) Total patients’ numbers at each factor levels
Dim ave() 0Redim ave(n) Average of patients’ numbers at each factor levels
Dim sq() 0Redim sq(n,p) Sum of squares of ‘‘deviation from mean’’ at each factor levels
Dim sa() 0Redim sa(n,p) Standard deviation at each factor levels
Dim var() 0Redim var(p) Amount of overall imbalance suppose patient allocated to each treatment
// Calculate the standard deviation at each factor levels. (n,p is got from previous page, and the patient’s number in each
factor levels and treatments already being recruited has been load into s(n,p).)
Redim x(n)
for i=1 to nx(i)=0
for j=1 to px(i)=x(i)+s(i,j)
next
ave(i)=(x(i)+1)/p
for j= 1 to p
sum=0
for h=1 to p
if h=j then
sum=sum+(s(i,h)+1-ave(i))*(s(i,h)+1-ave(i))
else
sum=sum+(s(i,h)-ave(i))*(s(i,h)-ave(i))
end if
next
sa(i,j)=Sqr(sum/p)
next
next
// Calculate the amount of overall imbalance suppose patient allocated to each treatment. (w(i) has been read from
database.)
for i=1 to pvar(i)=0
for j=1 to nvar(i)=var(i)+sa(j,i)*w(j)
next
next
Appendix B. Programming code for patients’ allocation
Dim p1 0The assignment probability
Dim ran 0Random number created by computer
Dim var() 0Redim var(p) Amount of overall imbalance suppose patient allocated to each treatment
Dim a() 0Redim a(p) Record the initial position of each treatment when sorting the overall imbalance
for i =1 to p
a(i)=i
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call sort()
//Sort var(i) in ascending order, and at the same time, a(i) record its initial position in the array.
function sort()
Dim i,j,temp,temp_afor i = 1 to p
for j = i + 1 to pIf var(i) > var(j) Then
temp = var(i)
temp_a=a(i)
var(i) = var(j)
a(i)=a(j)
var(j) = temp
a(j)=temp_a
end if
next
next
Dim m 0The number of smallest and equalGk
Dim k 0The treatment group number to which the patient is to be allocated
m=1
for i=1 to p-1if var(i)=var(i+1) then
m=m+1
else
exit for
end if
next
if m=1 then
for i=1 to p
randomize() 0Use the return value of system timer function as the seed of randomization
ran=rnd()
If i=p or ran < p1 Then
k=a(i)
exit for
End If
next
else
randomize()
ran=rnd()
r=int(ran*1000) mod m ’Get number from ‘‘0 to m-1’’ randomly
k=a(r+1)
end if
//This patient would be allocated to treatment k
Appendix C. Programming code in SQL for setting blind
CREATE PROCEDURE preblind
@study_id smallint,
@center_id smallint
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DECLARE @medicine_num smallint – The biggest drug number for certain study and center.
DECLARE @block_num smallint – The biggest block number in current study.
DECLARE @counter smallint
DECLARE @t real – computer generated random number.
DECLARE @blocksize smallint – The block length in current study.
DECLARE @treatment smallint – The number of treatment arms in current study.
DECLARE @n smallint – The number of same treatment arms in each block.
DECLARE @m smallintBEGIN
IF (select max(medicine_num) from blind where study_id=@study_id) is null
SET @medicine_num=0
SET @block_num=0
END
ELSE
BEGIN
select @medicine_num= (select max(medicine_num) from blind where study_id=@study_id)
select @block_num= (select max(block_num) from blind where study_id=@study_id)
END
select @blocksize = (select blocksize from study where study_id=@study_id)
select @treatment = (select tr_gro_num from study where study_id=@study_id)
SET @counter=@medicine_num+1
WHILE @counter < =@medicine_num+@blocksize– Insert random num into blind table
BEGINselect @t = RAND()
BEGIN
insert into blind (center_id,study_id,medicine_num,block_num,ran) values (@center_id,@study_id,@counter,
@block_num+1,@t)
END
SET NOCOUNT ON
SET @counter = @counter + 1
SET NOCOUNT OFF
END
–insert allocation number into blind table according to the ranking of random number
SET @counter=@medicine_num+1
WHILE @counter < = @medicine_num +@blocksize
BEGIN
IF @counter=@medicine_num+@blocksize
update blind SET allo_num=@counter where center_id=@center_id and study_id=@study_id and allo_num=0 and
medicine_num between (@medicine_num+1) and (@medicine_num+@blocksize)
ELSE
update blind set allo_num=@counter
where ran = (select min(ran) from blind where center_id=@center_id and study_id=@study_id and allo_num=0 and
medicine_num between (@medicine_num+1) and (@medicine_num+@blocksize))
BEGIN
SET NOCOUNT ON
SET @counter = @counter + 1
SET NOCOUNT OFF
END
END
–insert treatment number into blind table according to the ranking of random number
SET @counter=@medicine_num+1
SET @n=@blocksize/@treatment
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WHILE @counter < = @medicine_num + @blocksize
BEGIN
update blind set treatment=@m where allo_num=@counter
BEGINSET NOCOUNT ON
SET @counter = @counter + 1
SET NOCOUNT OFF
END
IF @counter > @medicine_num + @n*@m
SET @m = @m + 1
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